US2022340883A1PendingUtilityA1
USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
Est. expiryJan 8, 2033(~6.5 yrs left)· nominal 20-yr term from priority
Y02A50/30C12N 2710/16651C12N 7/00C12N 2710/16643A61K 39/245
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
Claims
exact text as granted — not AI-modified1 - 8 . (canceled)
9 . A method for producing an HSV-1 d27.1 vector comprising:
(a) infecting V27 cells with HSV-1 d27.1 vector; and (b) culturing said infected V27 cells in a cell culture medium comprising valproic acid or dexamethasone in an amount that increases HSV-1 d27.1 viral titer.
10 . (canceled)
11 . The method of claim 9 , wherein said cell culture medium further comprises serum.
12 . The method of claim 11 , wherein the serum is fetal bovine serum.
13 - 14 . (canceled)
15 . A method for producing herpes simplex virus (HSV) comprising culturing cells infected with said HSV in a cell culture medium that comprises valproic acid or dexamethasone in an amount that increases yield of the HSV as compared with a cell culture medium that lacks the valproic acid or dexamethasone.
16 . The method of claim 15 , wherein said HSV is herpes simplex-1 virus (HSV-1).
17 . The method of claim 16 , wherein said HSV-1 is a wild-type HSV-1.
18 . The method of claim 16 , wherein said HSV-1 is a recombinant HSV-1.
19 . The method of claim 15 , wherein the cells are 293 or Vero cells.
20 . The method of claim 19 , wherein the cells are Vero cells that are V27 cells.
21 . The method of claim 15 , wherein the cell culture medium further comprises serum.
22 . The method of claim 21 , wherein the serum is fetal bovine serum.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.